New Patent Battles Emerge Over What Lipid Technology Is Used In mRNA COVID-19 Vaccines

 
• By Brenda Sandburg

Alnylam seeks royalties, claiming its lipid nanoparticle technology is a component of both Moderna’s and Pfizer’s vaccines. Moderna calls Alnylam’s suit ‘blatant opportunism.’ Acuitas sues Arbutus seeking declaratory judgement that Comirnaty does not infringe its LPN technology.

mRNA vaccines
Lipid technology used in mRNA COVID-19 vaccines is at center of patent suits • Source: Alamy

More from Vaccines

More from Pink Sheet